Malaysia Diabetes Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 389.13 Million |
| Market Size (2029) | USD 423.21 Million |
| CAGR (2024 - 2029) | 3.10 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Malaysia Diabetes Drugs Market Analysis
The Malaysia Diabetes Care Drugs Market size is estimated at USD 389.13 million in 2024, and is expected to reach USD 423.21 million by 2029, growing at a CAGR of 3.10% during the forecast period (2024-2029).
Malaysia's Ministry of Health reported 5,809 new COVID-19 cases in 24 hours, comprising 5,782 locally infected and 27 imported cases, increasing the national total to 2,541,147. So far, about 78.4 percent of the Malaysian population has gotten at least one dose of the COVID-19 vaccine, with 75.9 percent completely vaccinated. According to the Health Ministry, four out of every ten patients who died from COVID-19 in Malaysia this year had diabetes. Diabetes affects one in every five Malaysians, or around 3.9 million persons aged 18 and up.
The number of young diabetics is increasing. Diabetes is becoming more common in younger individuals, with the number of diabetics aged 18 to 40 more than tripling in the last 15 years. The growing population of diabetics means a greater burden of the illness and its consequences, including heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation.
In reality, underlying comorbidities account for most coronavirus mortality in Malaysia, with diabetes and hypertension leading the list.
In terms of medicines, the insulin category commands a sizable market share. Over 100 million people worldwide use insulin, including all persons with Type 1 diabetes and 10% to 25% of people with Type 2 diabetes. Insulin production is extremely sophisticated, and only a few insulin manufacturers are on the market. As a result, there is fierce rivalry among these producers, who continually strive to satisfy patients' demands by providing the highest-quality insulin.
Malaysia Diabetes Drugs Market Trends
Oral-Anti Diabetes Drugs is having the highest market share in the Current Year
The Oral-Anti Diabetes Drugs segment is expected to increase with a CAGR of over 3.7% during the forecast period, mainly due to the demand from the diabetes population, which was more than 4.2 million by the end of 2022.
Malaysia has the highest diabetes rate in the Western Pacific and one of the highest in the world, with an annual cost of roughly 600 million US dollars. Various variables contribute to the trend, including population increase, aging, urbanization, and rising obesity and physical inactivity rates. The growing prevalence of diabetes and its effects in Malaysia prompted this study to comprehensively identify, describe, and quantify Malaysia's pooled prevalence of diabetes and prediabetes.
Insulin therapy is the most potent hypoglycaemic medication currently available for diabetes treatment; however, the potency of insulin deteriorates if it is stored under improper conditions. In Malaysia, NCDs, including diabetes, account for more than 70% of all deaths. Obesity leads to a more than seven times increase in the risk of developing type 2 diabetes, while being overweight increases the risk by three times.
The Malaysia government's encouragement increased the usage of Management Devices over the forecast period.
Increasing Diabetes population in Malaysia
Diabetes and prediabetes are on the rise in Malaysia, hence the Malaysian government is implementing diabetes prevention and management programs throughout the country. To minimize the prevalence of diabetes in the country, the Malaysian government should develop a comprehensive approach and plan to enhance diabetes knowledge, control, prevention, and treatment. Being overweight and obese are major contributors to Malaysia's younger diabetic population. According to a recent NHMS, one in every two adults in Malaysia is overweight or obese.
Diabetes patients have excessive levels of glucose or sugar in their blood. It is a condition caused by the body's inability to produce enough insulin to manage blood sugar levels. It can also be caused by the body's inefficient utilization of insulin, which is known as insulin resistance. Obesity, bad eating habits, sedentary lifestyles, and heredity are all factors that contribute to this process. According to current figures from the ministry's National Diabetes Registry (NDR), 84% of diabetic patients in Malaysia are overweight, with young Malaysians aged 18 to 40 being among them. The ministry is now investigating the Sama-Sama program, which aims to empower family members and caregivers to offer support for persons living with diabetes to enhance disease control and outcomes. The ministry is collaborating with the commercial sector on the program to train healthcare personnel and, subsequently, carers.
Thus, owing to the above factors it is expected to drive the market growth over the forecast period.
Malaysia Diabetes Drugs Industry Overview
The diabetes drugs market is moderately fragmented, with few significant generic players. A few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb, dominate the insulin drugs and Sglt-2 drugs market. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, players are tapping into new markets to increase their market shares, especially in emerging economies where the demand is very high compared to the supply.
Malaysia Diabetes Drugs Market Leaders
-
Eli Lilly
-
Boehringer Ingelheim
-
Astrazeneca
-
Sanofi
-
NovoNordisk
*Disclaimer: Major Players sorted in no particular order
Malaysia Diabetes Drugs Market News
- October 2023: The U.S. Food and Drug Administration (USFDA) has classified Biocon Biologics' insulin manufacturing facility in Johor, Malaysia as an official action indicated (OAI).
- May 2022: Tirzepatide (Mounjaro) was approved for treating Type 2 diabetes in adults. Tirzepatide's FDA approval marks the first in a new class of diabetes medications: a dual GIP/GLP-1 receptor agonist.
- March 2022: Oramed announced that ORMD-0801 is being evaluated in two pivotal Phase 3 trials and can be the first oral insulin capsule that has the most convenient and safest way to deliver insulin therapy. This drug is expected to be a game-changer in the insulin and oral anti-diabetes drugs markets. Oramed is also developing an oral GLP-1 analog capsule (ORMD-0901).
Malaysia Diabetes Drugs Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Oral Anti-diabetic drugs
- 5.1.1 Biguanides
- 5.1.1.1 Metformin
- 5.1.2 Alpha-Glucosidase Inhibitors
- 5.1.2.1 Alpha-Glucosidase Inhibitors
- 5.1.3 Dopamine D2 receptor agonist
- 5.1.3.1 Bromocriptin
- 5.1.4 SGLT-2 inhibitors
- 5.1.4.1 Invokana (Canagliflozin)
- 5.1.4.2 Jardiance (Empagliflozin)
- 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
- 5.1.4.4 Suglat (Ipragliflozin)
- 5.1.5 DPP-4 inhibitors
- 5.1.5.1 Onglyza (Saxagliptin)
- 5.1.5.2 Tradjenta (Linagliptin)
- 5.1.5.3 Vipidia/Nesina(Alogliptin)
- 5.1.5.4 Galvus (Vildagliptin)
- 5.1.6 Sulfonylureas
- 5.1.6.1 Sulfonylureas
- 5.1.7 Meglitinides
- 5.1.7.1 Meglitinides
-
5.2 Insulins
- 5.2.1 Basal or Long Acting Insulins
- 5.2.1.1 Lantus (Insulin Glargine)
- 5.2.1.2 Levemir (Insulin Detemir)
- 5.2.1.3 Toujeo (Insulin Glargine)
- 5.2.1.4 Tresiba (Insulin Degludec)
- 5.2.1.5 Basaglar (Insulin Glargine)
- 5.2.2 Bolus or Fast Acting Insulins
- 5.2.2.1 NovoRapid/Novolog (Insulin Aspart)
- 5.2.2.2 Humalog (Insulin Lispro)
- 5.2.2.3 Apidra (Insulin Glulisine)
- 5.2.3 Traditional Human Insulins
- 5.2.3.1 Novolin/Actrapid/Insulatard
- 5.2.3.2 Humulin
- 5.2.3.3 Insuman
- 5.2.4 Biosimilar Insulins
- 5.2.4.1 Insulin Glargine Biosimilars
- 5.2.4.2 Human Insulin Biosimilars
-
5.3 Combination drugs
- 5.3.1 Insulin combinations
- 5.3.1.1 NovoMix (Biphasic Insulin Aspart)
- 5.3.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
- 5.3.1.3 Xultophy (Insulin Degludec and Liraglutide)
- 5.3.2 Oral Combinations
- 5.3.2.1 Janumet (Sitagliptin and Metformin)
-
5.4 Non-Insulin Injectable drugs
- 5.4.1 GLP-1 receptor agonists
- 5.4.1.1 Victoza (Liraglutide)
- 5.4.1.2 Byetta (Exenatide)
- 5.4.1.3 Bydureon (Exenatide)
- 5.4.1.4 Trulicity (Dulaglutide)
- 5.4.1.5 Lyxumia (Lixisenatide)
- 5.4.2 Amylin Analogue
- 5.4.2.1 Symlin (Pramlintide)
6. MARKET INDICATORS
- 6.1 Type-1 Diabetic Population
- 6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Takeda
- 7.1.2 Novo Nordisk
- 7.1.3 Pfizer
- 7.1.4 Eli Lilly
- 7.1.5 Janssen Pharmaceuticals
- 7.1.6 Astellas
- 7.1.7 Boehringer Ingelheim
- 7.1.8 Merck And Co.
- 7.1.9 AstraZeneca
- 7.1.10 Bristol Myers Squibb
- 7.1.11 Novartis
- 7.1.12 Sanofi
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityMalaysia Diabetes Drugs Industry Segmentation
Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin the body's cells do not respond properly to insulin, or both. Malaysia's diabetes care drugs market witnessed USD 339 million in the current year and is anticipated to register a cagr of over 3% during the forecast period. Malaysia's diabetes care drugs market is segmented into drugs. The report offers the market size in value terms in USD for all the abovementioned segments.
| Oral Anti-diabetic drugs | Biguanides | Metformin |
| Oral Anti-diabetic drugs | Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors |
| Oral Anti-diabetic drugs | Dopamine D2 receptor agonist | Bromocriptin |
| Oral Anti-diabetic drugs | SGLT-2 inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| Oral Anti-diabetic drugs | DPP-4 inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina(Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Oral Anti-diabetic drugs | Sulfonylureas | Sulfonylureas |
| Oral Anti-diabetic drugs | Meglitinides | Meglitinides |
| Insulins | Basal or Long Acting Insulins | Lantus (Insulin Glargine) |
| Levemir (Insulin Detemir) | ||
| Toujeo (Insulin Glargine) | ||
| Tresiba (Insulin Degludec) | ||
| Basaglar (Insulin Glargine) | ||
| Insulins | Bolus or Fast Acting Insulins | NovoRapid/Novolog (Insulin Aspart) |
| Humalog (Insulin Lispro) | ||
| Apidra (Insulin Glulisine) | ||
| Insulins | Traditional Human Insulins | Novolin/Actrapid/Insulatard |
| Humulin | ||
| Insuman | ||
| Insulins | Biosimilar Insulins | Insulin Glargine Biosimilars |
| Human Insulin Biosimilars | ||
| Combination drugs | Insulin combinations | NovoMix (Biphasic Insulin Aspart) |
| Ryzodeg (Insulin Degludec and Insulin Aspart) | ||
| Xultophy (Insulin Degludec and Liraglutide) | ||
| Combination drugs | Oral Combinations | Janumet (Sitagliptin and Metformin) |
| Non-Insulin Injectable drugs | GLP-1 receptor agonists | Victoza (Liraglutide) |
| Byetta (Exenatide) | ||
| Bydureon (Exenatide) | ||
| Trulicity (Dulaglutide) | ||
| Lyxumia (Lixisenatide) | ||
| Non-Insulin Injectable drugs | Amylin Analogue | Symlin (Pramlintide) |
Malaysia Diabetes Drugs Market Research FAQs
How big is the Malaysia Diabetes Care Drugs Market?
The Malaysia Diabetes Care Drugs Market size is expected to reach USD 389.13 million in 2024 and grow at a CAGR of 3.10% to reach USD 423.21 million by 2029.
What is the current Malaysia Diabetes Care Drugs Market size?
In 2024, the Malaysia Diabetes Care Drugs Market size is expected to reach USD 389.13 million.
Who are the key players in Malaysia Diabetes Care Drugs Market?
Eli Lilly, Boehringer Ingelheim, Astrazeneca, Sanofi and NovoNordisk are the major companies operating in the Malaysia Diabetes Care Drugs Market.
What years does this Malaysia Diabetes Care Drugs Market cover, and what was the market size in 2023?
In 2023, the Malaysia Diabetes Care Drugs Market size was estimated at USD 377.07 million. The report covers the Malaysia Diabetes Care Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Malaysia Diabetes Care Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Malaysia Diabetes Drugs Industry Report
Statistics for the 2024 Malaysia Diabetes Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Malaysia Diabetes Drugs analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
